Cipher Pharmaceuticals reported a strong earnings quarter with record net revenue, driven by the Natroba business. Despite some challenges in the U.S. licensing revenue and legal costs, the company's strategic initiatives and capital allocation were highlighted as positive aspects.

Company Guidance -

Q3 2025

During the call, Cipher Pharmaceuticals provided guidance for their Q2 2025 results, highlighting a record-breaking quarter for total net revenue driven by the strong performance of their U.S. Natroba business, which generated $7.8 million in revenue with a gross margin of 86%. Overall, the company's total net revenue for Q2 2025 was $13.4 million, marking a 152% increase compared to the same quarter in 2024. The Natroba business, acquired in July 2024, contributed significantly to this growth, with revenues for the first six months of 2025 reaching $14.4 million. Cipher's base business also performed well, with revenues of $5.6 million, marking a 6% increase from Q2 2024. Adjusted EBITDA for the quarter was $7.6 million, up 148% from the previous year, and the company maintained a strong cash position with $11.3 million in cash and $25 million in debt at the end of the quarter. The company emphasized its growth strategy, focusing on expanding Natroba's presence in the U.S., launching in Canada, and pursuing global opportunities, while also exploring complementary product acquisitions and partnerships.

Record Net Revenue

Cipher achieved the highest earnings quarter for total net revenue in its history, with a 152% increase compared to the same quarter in the prior year.

Strong Performance from Natroba Business

Natroba business revenues were $7.8 million in Q2 2025, exceeding expectations and contributing significantly to the overall revenue growth.

Adjusted EBITDA Growth

Adjusted EBITDA for Q2 2025 was $7.6 million, an increase of 148% from the same quarter last year.

Progress in Strategic Initiatives

Continued progress on launching Natroba in Canada and pursuing global out-licensing opportunities.

Effective Capital Allocation

Cipher made a $15 million repayment on its revolving credit facility and repurchased $2.1 million of common shares.

Cipher Pharmaceuticals (TSE:CPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:CPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.20 / -	0.014	―	―	―
Aug 07, 2025	2025 (Q2)	0.22 / 0.30	0.165	83.33% (+0.14)	―
May 08, 2025	2025 (Q1)	0.15 / 0.14	0.276	-50.00% (-0.14)
Mar 18, 2025	2024 (Q4)	0.26 / 0.18	0.413	-56.67% (-0.23)	―
Nov 07, 2024	2024 (Q3)	0.19 / 0.01	0.372	-96.30% (-0.36)	―
Aug 08, 2024	2024 (Q2)	0.16 / 0.17	0.165	0.00% (0.00)	―
May 09, 2024	2024 (Q1)	0.14 / 0.28	0.138	100.00% (+0.14)	―
Mar 14, 2024	2023 (Q4)	0.13 / 0.41	1.075	-61.54% (-0.66)	―
Nov 09, 2023	2023 (Q3)	0.10 / 0.37	0.138	170.00% (+0.23)	―
Aug 10, 2023	2023 (Q2)	0.12 / 0.17	0.11	50.00% (+0.06)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:CPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	C$13.54	C$15.40	+13.74%
May 08, 2025	C$14.42	C$13.91	-3.54%
Mar 18, 2025	C$11.98	C$13.45	+12.27%
Nov 07, 2024	C$15.54	C$13.88	-10.68%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cipher Pharmaceuticals (TSE:CPH) report earnings?

Cipher Pharmaceuticals (TSE:CPH) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Cipher Pharmaceuticals (TSE:CPH) earnings time?

Cipher Pharmaceuticals (TSE:CPH) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:CPH EPS forecast?

TSE:CPH EPS forecast for the fiscal quarter 2025 (Q3) is 0.2.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing